140 related articles for article (PubMed ID: 8631853)
1. Programming the Rous sarcoma virus protease to cleave new substrate sequences.
Ridky TW; Bizub-Bender D; Cameron CE; Weber IT; Wlodawer A; Copeland T; Skalka AM; Leis J
J Biol Chem; 1996 May; 271(18):10538-44. PubMed ID: 8631853
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases.
Cameron CE; Ridky TW; Shulenin S; Leis J; Weber IT; Copeland T; Wlodawer A; Burstein H; Bizub-Bender D; Skalka AM
J Biol Chem; 1994 Apr; 269(15):11170-7. PubMed ID: 8157644
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites.
Ridky TW; Cameron CE; Cameron J; Leis J; Copeland T; Wlodawer A; Weber IT; Harrison RW
J Biol Chem; 1996 Mar; 271(9):4709-17. PubMed ID: 8617736
[TBL] [Abstract][Full Text] [Related]
4. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.
Ridky TW; Kikonyogo A; Leis J; Gulnik S; Copeland T; Erickson J; Wlodawer A; Kurinov I; Harrison RW; Weber IT
Biochemistry; 1998 Sep; 37(39):13835-45. PubMed ID: 9753473
[TBL] [Abstract][Full Text] [Related]
5. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates.
Grinde B; Cameron CE; Leis J; Weber IT; Wlodawer A; Burstein H; Skalka AM
J Biol Chem; 1992 May; 267(14):9491-8. PubMed ID: 1315756
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for specificity of retroviral proteases.
Wu J; Adomat JM; Ridky TW; Louis JM; Leis J; Harrison RW; Weber IT
Biochemistry; 1998 Mar; 37(13):4518-26. PubMed ID: 9521772
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
[TBL] [Abstract][Full Text] [Related]
9. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
[TBL] [Abstract][Full Text] [Related]
10. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
11. Mutations that alter the activity of the Rous sarcoma virus protease.
Grinde B; Cameron CE; Leis J; Weber IT; Wlodawer A; Burstein H; Bizub D; Skalka AM
J Biol Chem; 1992 May; 267(14):9481-90. PubMed ID: 1315755
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases.
Cameron CE; Grinde B; Jacques P; Jentoft J; Leis J; Wlodawer A; Weber IT
J Biol Chem; 1993 Jun; 268(16):11711-20. PubMed ID: 8389361
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
Beck ZQ; Lin YC; Elder JH
J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
[TBL] [Abstract][Full Text] [Related]
15. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.
Kádas J; Weber IT; Bagossi P; Miklóssy G; Boross P; Oroszlan S; Tözsér J
J Biol Chem; 2004 Jun; 279(26):27148-57. PubMed ID: 15102858
[TBL] [Abstract][Full Text] [Related]
16. Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease.
Menéndez-Arias L; Weber IT; Soss J; Harrison RW; Gotte D; Oroszlan S
J Biol Chem; 1994 Jun; 269(24):16795-801. PubMed ID: 8207003
[TBL] [Abstract][Full Text] [Related]
17. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
[TBL] [Abstract][Full Text] [Related]
18. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.
Dauber DS; Ziermann R; Parkin N; Maly DJ; Mahrus S; Harris JL; Ellman JA; Petropoulos C; Craik CS
J Virol; 2002 Feb; 76(3):1359-68. PubMed ID: 11773410
[TBL] [Abstract][Full Text] [Related]
19. Interactions of substrates and inhibitors with a family of tethered HIV-1 and HIV-2 homo- and heterodimeric proteinases.
Griffiths JT; Tomchak LA; Mills JS; Graves MC; Cook ND; Dunn BM; Kay J
J Biol Chem; 1994 Feb; 269(7):4787-93. PubMed ID: 8106448
[TBL] [Abstract][Full Text] [Related]
20. Analysis of substrate cleavage by recombinant protease of human T cell leukaemia virus type 1 reveals preferences and specificity of binding.
Daenke S; Schramm HJ; Bangham CR
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2233-9. PubMed ID: 8077922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
